Skip to main content
. 2023 Sep 4;13:44. doi: 10.1186/s13561-023-00457-4

Table 2.

Base case cost-effectiveness results estimated over the lifetime, discounted

Strategies Costs (USD) QALYs ∆C ∆QALYs Incremental Cost per QALY Gained (valsartan vs. enalapril)
Valsartan 119,645.45 16.15 6,625.77 0.99 6,692.69
Enalapril 113,019.68 15.16
Candesartan 113,093.37 15.06 Dominated

QALYs = Quality-adjusted life years; ∆C = cost difference; ∆QALY = QALY difference